Cortex gets OK to resume enrollment for Ampakine trials

July 17 (Reuters) - Cortex Pharmaceuticals Inc. (COR.A) said it has received approval from U.S. regulators to resume enrollment for clinical trials of its drug candidate, Ampakine CX717, in Alzheimer PET-scan studies .

The trial will resume at all dose levels.

The study of Ampakine CX717, which was originally designed with doses of 200mg, 600mg and 1200mg, was placed on hold by the U.S. Food and Drug Administration due to concerns over some preclinical animal data. (Reporting by Shailesh Kuber in Bangalore)